Greenwich LifeSciences’ LD Micro Presentation Replay Now Available
January 05 2021 - 6:00AM
Business Wire
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a
clinical-stage biopharmaceutical company focused on the development
of GP2, an immunotherapy to prevent breast cancer recurrences in
patients who have previously undergone surgery, today announced
that a replay of its December 15, 2020 presentation and Q&A
session by a panel of investors from the Annual LD Micro Main Event
(XIII) is now available.
In the presentation, Snehal Patel, CEO of Greenwich
LifeSciences, discusses the Company’s development of GP2, including
the recently published Phase IIb trial final efficacy data showing
100% disease free survival or 0% breast cancer recurrences in HER2
positive patients over 5 years of follow-up, an overview of the
planned Phase III trial, and upcoming milestones.
To view the replay directly, please click here. To view the replay from the LD Micro main
page, please navigate to the Tuesday schedule under Track 2.
About LD Micro
LD Micro is the host of the most influential conferences in the
small-cap world. LD Micro was founded in 2006 with the sole purpose
of being an independent resource in the microcap space. What
started out as a newsletter highlighting unique companies has
transformed into several influential events annually (Invitational,
Summit, and Main Event). With the recent SRAX acquisition, LD has
access to the largest active base of microcap investors in the
world at over 2 million and counting. For more information, please
visit the conference website at: https://ve.mysequire.com/
About Breast Cancer and HER2/neu Positivity
One in eight U.S. women will develop invasive breast cancer over
her lifetime, with approximately 266,000 new breast cancer patients
and 3.1 million breast cancer survivors in 2018. HER2/neu (human
epidermal growth factor receptor 2) protein is a cell surface
receptor protein that is expressed in a variety of common cancers,
including in 75% of breast cancers at low (1+), intermediate (2+),
and high (3+ or over-expressor) levels.
About Greenwich LifeSciences, Inc.
Greenwich LifeSciences is a clinical-stage biopharmaceutical
company focused on the development of GP2, an immunotherapy to
prevent breast cancer recurrences in patients who have previously
undergone surgery. GP2 is a 9 amino acid transmembrane peptide of
the HER2/neu protein. In a randomized, single-blinded,
placebo-controlled, multi-center (16 sites led by MD Anderson
Cancer Center) Phase IIb clinical trial, no recurrences were
observed in the HER2/neu 3+ adjuvant setting after median 5 years
of follow-up, if the patient received the 6 primary intradermal
injections over the first 6 months (p = 0.0338). Of the 138
patients that have been treated with GP2 to date over 4 clinical
trials, GP2 treatment was well tolerated and no serious adverse
events were observed related to GP2 immunotherapy. Greenwich
LifeSciences is planning to commence a Phase III clinical trial
using a similar treatment regime as the Phase IIb clinical trial.
For more information on Greenwich LifeSciences, please visit the
Company’s website: www.greenwichlifesciences.com.
Forward-Looking Statement Disclaimer
Statements in this press release contain “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” "will” “would,” or the negative of these
words or other similar expressions, although not all
forward-looking statements contain these words. Forward-looking
statements are based on Greenwich LifeSciences Inc.’s current
expectations and are subject to inherent uncertainties, risks and
assumptions that are difficult to predict, including statements
regarding the intended use of net proceeds from the public
offering; consequently, actual results may differ materially from
those expressed or implied by such forward-looking statements.
Further, certain forward-looking statements are based on
assumptions as to future events that may not prove to be accurate.
These and other risks and uncertainties are described more fully in
the section titled “Risk Factors” in the final prospectus related
to the public offering filed with the SEC. Forward-looking
statements contained in this announcement are made as of this date,
and Greenwich LifeSciences, Inc. undertakes no duty to update such
information except as required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210105005390/en/
Company Contact Snehal Patel Investor Relations (832)
819-3232 info@greenwichlifesciences.com Investor
& Public Relations Contact for Greenwich LifeSciences Dave
Gentry RedChip Companies Inc. Office: 1-800-RED CHIP (733 2447)
Cell: (407) 491-4498 dave@redchip.com
Greenwich LifeSciences (NASDAQ:GLSI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Greenwich LifeSciences (NASDAQ:GLSI)
Historical Stock Chart
From Apr 2023 to Apr 2024